Taxane resistance in prostate cancer is mediated by decreased drug-target engagementAda Gjyrezi, Rupal S. Bhatt|Journal of Clinical Investigation|2020Cited by 53
Early Actions of Anti–Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood VesselsBasel Sitohy, Harold F. Dvorak, Janice A. Nagy et al.|American Journal Of Pathology|2017Cited by 37
Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving ResistanceRana R. McKay, Mary‐Ellen Taplin, Lucia Kwak et al.|Clinical Cancer Research|2021Cited by 32
A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).Lauren C. Harshman, Mäneka Puligandla, Naomi B. Haas et al.|Journal of Clinical Oncology|2017Cited by 12
Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell CarcinomaXīn Gào, Rupal S. Bhatt, Opeyemi A. Jegede et al.|Clinical Genitourinary Cancer|2018Cited by 8